attomol^® PAI-1 Quicktype

The assay attomol^® PAI-1 Quicktype is used for the supportive diagnosis of thrombophilia. This test can be used to determine the 4G/5G dimorphism in the promoter region of the human PAI-1 gene (rs1799889). It is a manual, qualitative assay using an allel-specific PCR with integrated probe hybridisation. The evaluation takes place by agarose gel electrophoresis, which can be carried out manually or automatically. The sample materialhas to be genomic DNA prepared from EDTA or citrate blood.

The  plasminogen  activator  inhibitor  1  (PAI-1)  neutralises  the  tissue  plasminogen  activator  (t-PA)  during fibrinolysis.  In  this  process,  limited  plasmin  formation  restricts  the  cleavage  of  fibrin.  An  excess  of  PAI-1 disturbs the fibrinolytic system because fibrin accumulates in blood vessels. Therefore, an enhanced plasma concentration of PAI-1 is under discussion as a risk factor for thrombosis [Sartori et al., 1998, Thromb Haemost, 80:956-960]. One reason for a PAI-1 excess in the plasma may be the 4G/5G dimorphism in the promoter region of the PAI-1 gene that is inherited autosomal-recessively. The polymorphism is caused by the deletion of guanine in the position -675 of the PAI-1 gene. The 4G allele causes enhanced gene transcription by only binding oftranscription activator. In contrast, the 5G wild type allele also binds the repression factor. The loss of the binding of the repression factor to the 4G/4G genotype leads to a 25 % rise of the PAI-1 plasma concentration compared with carriers of the 5G/5G genotype [Kohler and Grant, 2000, N. Engl. J. Med., 342:1792-1801]. The prevalence of the 4G/4G genotype is between 28 and 31 % in the German, Austrian and Czech population [Kvasnicka T. et al., 2014, Physiol Res., 63, 245-253].

• PCR-H₂O
• PCR-buffer IV
• primer PAI-1
• instructions for use

You can find more informations about Quicktype-Technology here.